Ulku Korkmaz

Ulku Korkmaz

Auto-generated profile, based on publicly available information

Ulku Korkmaz

Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in Acta Cardiologica
Verified
Journal Article
Closed access
LLLampros Lakkas
Lampros Lakkas
BSBurcu Dirlik Serim
Burcu Dirlik Serim
AFAndreas Fotopoulos
Andreas Fotopoulos
Ioannis IakovouIoannis Iakovou
Ioannis Iakovou
ADArgyrios Doumas
Argyrios Doumas
Chrissa SiokaChrissa Sioka
Chrissa Sioka
There has been a recent rise in the use of implantable cardiac devices, mostly valves but also electronic ones, such as pacemakers, and implantable defibrillators. The increasing use of these devices had as a consequence the raised incidence of endocarditis, an infrequent but morbid complication of these procedures. Thus, early diagnosis of the implantable cardiac devices related infection and endocarditis became pivotal for appropriate management. For diagnostic purposes, the modified Duke criteria are widely used, which are based on clinical and imaging findings, in addition to serological analyses and blood cultures. 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is a recently employed method in order to improve the early diagnosis of endocarditis as well as infection of the implantable device. It is likely, that combining the modified Duke criteria with the FDG PET/CT, will increase the sensitivity and specificity of diagnosis and will guide the treating physician to an early and appropriate management.

5 September 2020 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
EUElif G. Umit
Elif G. Umit
UKUlku Korkmaz
Ulku Korkmaz
MBMehmet Baysal
Mehmet Baysal
SGSedanur Karaman Gulsaran
Sedanur Karaman Gulsaran
VBVolkan Bas
Volkan Bas
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir

14 September 2020 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
VBVolkan Bas
Volkan Bas
EUElif Gulsum Umit
Elif Gulsum Umit
UKUlku Korkmaz
Ulku Korkmaz
MBMehmet Baysal
Mehmet Baysal
SGSedanur Karaman Gulsaran
Sedanur Karaman Gulsaran
ADAhmet Muzafer Demir
Ahmet Muzafer Demir

1 February 2021 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
SSSelin Soyluoğlu
Selin Soyluoğlu
ÜKÜlkü Korkmaz
Ülkü Korkmaz
BÖBüşra Özdemir
Büşra Özdemir
GAGülay Durmuş Altun
Gülay Durmuş Altun
Gastrointestinal bleeding (GIB) is a life-threatening problem that requires a multidisciplinary approach for successful treatment. This study aims to emphasize the clinical contribution of single photon emission computed tomography/computed tomography (SPECT/CT) for the diagnosis of acute bleeding. All 14 patients referred to the nuclear medicine department in 3 years with suspicion of acute GIB were evaluated retrospectively. Clinical records were analyzed to assess the scintigraphic findings, emphasizing the correlative contribution of the CT portion on SPECT/CT studies. Five patients were negative on dynamic and static planar images. SPECT/CT was performed in 9 patients who had positive findings on planar imaging. SPECT/CT could identify the same bleeding site originating from the anastomosis in four patients with a history of abdominal surgery. SPECT/CT confirmed bleeding from the cecum in a patient with cervical cancer. SPECT/CT showed the bleeding focus in the bladder neck of a patient with bladder cancer and the bleeding from peritoneal metastases of a patient with gastric cancer. In 1 patient, the right upper quadrant activity accumulation, which may cause false positives, was found to be the gallbladder on SPECT/CT. Delayed images showed the true bleeding focus in the cecum. In 1 patient, suspicious activity accumulation in the midline of the abdomen was found to be due to a previously unknown aortic aneurysm on SPECT/CT. SPECT/CT imaging is a feasible technique to facilitate image interpretation in patients with GIB. SPECT/CT imaging can guide the surgeon through more accurate localization. Therefore, for proper patient management, SPECT/CT should be applied to detect the bleeding focus, if present, especially in patients who had undergone a previous operation.

15 May 2020 in Polish Journal of Radiology
Verified
Journal Article
Open access
UKUlku Korkmaz
Ulku Korkmaz
MHMuhammet Bekir Hacioglu
Muhammet Bekir Hacioglu
OKOsman Kostek
Osman Kostek
NSNecdet Sut
Necdet Sut
HKHilmi Kodaz
Hilmi Kodaz
GDGulay Durmus-Altun
Gulay Durmus-Altun
Purpose: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) combined with computed tomo­graphy (CT) scan is accepted as a standard tool in the staging of oesophageal cancer (OC). Histological subtype of tumour is known to be a major determinant of prognosis and metabolic behaviour. In this study, we aimed to evaluate the effect of histological subtypes of OC on standard uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) obtained by PET/CT, and also to compare this effect with prognosis.Material and methods: Images and clinical course data of 57 patients who were diagnosed with EC and treated in our hospital between 2009 and 2016 were evaluated in a retrospective manner. PET/CT images were re-analysed in terms of metabolic parameters, and observations were compared with histological subtypes.Results: No significant difference was observed between histological subtypes with SUVmax, overall survival (OS), or progression-free survival (PFS). Thus, MTV was observed to be related with histological subtype; MTV values of adenocancer patients were significantly higher than those of squamous cell cancer patients.Conclusions: Metabolic tumour volume was related with histological subtype of OC, but clinical staging, TLG, and SUVmax values were not related with histological subtype, which may suggest the use of MTV as a routine parameter for OC and inclusion of MTV observations in prognostic scoring.

29 September 2023 in Medicine
Verified
Journal Article
Open access
SSSelin Soyluoglu
Selin Soyluoglu
BABurak Andac
Burak Andac
UKUlku Korkmaz
Ulku Korkmaz
FUFunda Ustun
Funda Ustun
I-131 radioiodine (RAI) ablation removes postoperative residual tissue and facilitates follow-up in low- and intermediate-risk differentiated thyroid cancer (DTC). Although low doses have been reported to be as effective as higher doses for ablation, the doses administered still vary depending on the patient and the practitioner. We aimed to evaluate the ablation efficiency, complications, and length of stay (LOS) of patients with DTC treated with 3 different doses for ablation. Patients with DTC who received RAI therapy were retrospectively reviewed. One hundred thirty patients with low-intermediate-risk, according to American Thyroid Association classification, without known lymph nodes or distant metastases were included. Patients were divided into 3 groups as 30 to 50 mCi, 75 mCi, and 100 mCi. Residue thyroid and salivary glands were evaluated from 9 to 12 months post-RAI I-131 scans. No significant difference was found between groups regarding ablation success (P = .795). In multivariable analyses, pretreatment thyroglobulin (hazard ratio = 0.8, 95% confidence interval 0.601–0.952, P = .017) and anti- thyroglobulin antibody (hazard ratio = 1.0, 95% confidence interval 0.967–0.998, P = .024) were 2 independent predictors of ablation success. The mean LOS was 2.1 ± 0.3, 2.6 ± 0.6, and 2.9 ± 0.4 days, respectively, (P = .001). LOS rates of ≥ 3 days were 13.2%, 54.3%, and 84.8%, respectively. Mild decreases in hemoglobin, white blood cell (WBC), and platelet counts were observed in all groups after 6 weeks without any clinically significant findings. A lower rate of change in WBC counts was observed in the 30 to 50 mCi group compared to others. There was no dose-dependent difference regarding the early complaints questioned. Ablation with 30 to 50 mCi provides benefits such as shorter LOS, better patient comfort, less salivary gland dysfunction, and less WBC suppression, thus reducing costs without decreasing efficacy.